GU Cancers 2024 | Elucidating the role of VEGF inhibitors for urothelial carcinoma

Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the emerging role of VEGF inhibitors in patients with urothelial carcinoma. Conflicting evidence exists surrounding the role of VEGF inhibition in the first-line setting, where the LEAP-011 trial (NCT03898180) had to be halted early, but findings from the PemCab trial (NCT03534804) are promising. In the second-line setting, the Phase III MAIN-CAV trial (NCT05092958) of cabozantinib and avelumab is underway. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.